2024-10-18 - Analysis Report
## Johnson & Johnson (JNJ) Stock Analysis Report

**1. Performance Overview**

Johnson & Johnson (JNJ) is a multinational pharmaceutical, medical device, and consumer packaged goods company.  JNJ's cumulative return is **37.1%**, significantly lagging behind the S&P 500 (VOO) with a **136.93%** cumulative return. This results in a **-99.83%** relative performance compared to the S&P 500, meaning its performance is far below the benchmark index. The relative performance stands at the 4.96th percentile of its historical range.

**2. Recent Price Action**

As of today, JNJ's closing price is **$164.28**. The stock is currently trading above its **5-day moving average ($162.38)**, **20-day moving average ($161.87)**, and **60-day moving average ($162.23)**. This indicates a slight short-term upward momentum.

**3. Technical Indicators**

JNJ's RSI stands at **64.73**, suggesting the stock is slightly overbought. The PPO (Price Oscillator) is at **0.18**, indicating a positive price momentum. The recent 20-day relative divergence change of **-8.05** suggests a short-term downward trend. The expected return is **0.0%** over the next five years, indicating no expected outperformance against the S&P 500.

**4. Recent Earnings & Outlook**

| Date | EPS | Revenue |
|---|---|---|
| 2024-07-25 | 1.95 | 22.45 B$ |
| 2024-05-01 | 1.35 | 21.38 B$ |
| 2024-02-16 | 1.68 | 21.39 B$ |
| 2023-10-27 | 10.32 | 21.35 B$ |
| 2024-02-16 | 10.32 | 21.35 B$ |

JNJ has consistently exceeded revenue expectations, but its EPS has been volatile, with significant drops in recent quarters. The recent earnings report (2024-07-25) reported an EPS of **1.95**, **beating expectations** by **0.05** points. 

**5. News & Recent Developments**

Recent market outlook for JNJ is mixed. While the company's strong revenue performance and diversified business model remain attractive, concerns around regulatory pressures, lawsuits, and competition in its pharmaceutical and medical device segments persist.

Analysts are divided on JNJ's future prospects. While some analysts maintain a bullish outlook, citing the company's consistent revenue growth and global presence, others express caution due to the ongoing legal challenges and market volatility.

According to Finbold, JNJ's performance highlights include its consistent revenue growth, strong brand recognition, and focus on innovation. However, challenges include the impact of lawsuits, rising healthcare costs, and potential competition in the pharmaceutical and medical device markets.

**6. Summary**

JNJ's recent performance has been underwhelming compared to the S&P 500, but its current price action shows some short-term upward momentum.  Despite its strong revenue growth, the company faces challenges with its EPS volatility, legal issues, and competition. Its technical indicators suggest a slight overbought condition, and the expected return is low.  Overall, JNJ remains a solid company with a strong brand, but its future performance depends on its ability to navigate the challenges it faces.

**7. Conclusion**

JNJ's recent performance has been underwhelming, lagging significantly behind the broader market. While the company's revenue growth and diversified business model are positive, concerns regarding legal issues and market volatility persist.  Investors considering JNJ should weigh these factors carefully and monitor the company's progress in addressing these challenges.  
